Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av Risdiplam hos deltagare med typ I och typ II spinal muskelatrofi (SMA)

3 november 2026 uppdaterad av: Hoffmann-La Roche

En icke-interventionell, multricenterstudie som undersöker resultaten av risdiplam hos patienter med spinal muskelatrofi typ I och typ II

This multicenter, non-interventional, prospective study with a retrospective component aims to evaluate the real-world clinical outcomes, safety profile, and motor function improvements of Risdiplam treatment in participants with Type I and Type II Spinal Muscle Atrophy over 24 months of treatment.

The study will allow retrospective collection of medical history data and previous participants visits from the medical records.

Studieöversikt

Status

Rekrytering

Betingelser

Studietyp

Observationell

Inskrivning (Beräknad)

30

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Studera Kontakt Backup

  • Namn: Reference Study ID Number: ML45655 https://forpatients.roche.com/ No attachments to email below.
  • Telefonnummer: 888-662-6728 (U.S. Only)
  • E-post: global-roche-genentech-trials@gene.com

Studieorter

      • Cairo, Egypten, 11566
        • Rekrytering
        • Neurology Department, Ain Shams University Hospitals
      • Cairo, Egypten, DUMMY_VALUE
        • Rekrytering
        • Air Force Specialized Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

Inte äldre än 5 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The participants must have a confirmed diagnosis of 5q-autosomal recessive SMA type I or type II with at least two survival motor neuron 2 (SMN2) copies for which Risdiplam is prescribed as per the SmPC.

Beskrivning

Inclusion Criteria:

  • Maximum age to be 6 months for type I participants and 5 years for type II participants at the time of diagnosis.
  • Participants must start/have started treatment with Risdiplam within 6 months of diagnosis.
  • Participant to be receiving adequate nutrition and hydration at index date, in the opinion of the Investigator.
  • Participant to be adequately recovered from any acute illness at the time index date.

Exclusion Criteria:

  • Participants not receiving treatment for disease with Risdiplam according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling.
  • Participants not receiving the Roche studied medicinal product, but a biosimilar.
  • Concomitant or previous administration in any investigational drug or device study.
  • Concomitant or previous administration of approved treatment for SMA other than Risdiplam.
  • Unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system diseases at index date.
  • Participants requiring invasive ventilation or tracheostomy at index date.
  • Participants requiring awake non-invasive ventilation due to respiratory insufficiency or with awake hypoxemia with or without ventilator support or with history of respiratory failure or severe pneumonia, and have not fully recovered their pulmonary function at the time of index date.
  • Severe contractures of joints of lower limbs and upper limbs at the time of index date.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Risdiplam Observational Arm

Data will be collected before, during and after treatment from participants who receive risdiplam treatment according to standard of care and Summary of Product Characteristics (SmPC). Participant data will be collected only during routine clinical interactions, with no additional study visits mandated.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change From Index Date in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Score at Month 12
Tidsram: Baseline, Month 12

CHOP-INTEND assessment is performed for participants aged <2 years or aged >2 years who are not able to sit > 10 seconds as defined by the World Health Organization (WHO). Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes.

The index date (D1) is when the participant was administered the first dose of Risdiplam.

Baseline, Month 12
Change From Index Date in Hammersmith Functional Motor Scale Expanded (HFMSE) Score at Months 12
Tidsram: Baseline, Months 12

HFMSE assessment is performed for participants who are ≥ 2 years and are sitters or walkers. Items on the original HFMS were expanded to capture higher functioning in SMA patients using 13 relevant additional items adapted from the gross motor function measure (GMFM) with their scoring adapted to a three-point scale as in the original HFMS. The score ranges between 0 - 66, a higher score indicates a higher level of function.

The index date (D1) is when the participant was administered the first dose of Risdiplam.

Baseline, Months 12

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Överlevnad efter 24 månader
Tidsram: Vid månad 24
Vid månad 24
Tid till förlust av sväljfunktion bedömd av studieansvarig läkare
Tidsram: Upp till månad 24
Upp till månad 24
Change From Index Date in CHOP-INTEND Score at Month 24
Tidsram: Baseline, Month 24

CHOP-INTEND assessment is performed for participants aged <2 years or aged >2 years who are not able to sit > 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes.

The index date (D1) is when the participant was administered the first dose of Risdiplam.

Baseline, Month 24
Percentage of Participants with CHOP-INTEND Score Improvement ≥ 4 Points Compared to Index Date at Months 12 and 24
Tidsram: Baseline, Months 12 and 24

CHOP-INTEND assessment is performed for participants aged <2 years or aged >2 years who are not able to sit > 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes.

The index date (D1) is when the participant was administered the first dose of Risdiplam.

Baseline, Months 12 and 24
Percentage of Participants with CHOP-INTEND Score ≥ 40 at Months 12 and 24
Tidsram: At Months 12 and 24

CHOP-INTEND assessment is performed for participants aged <2 years or aged >2 years who are not able to sit > 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal orientated items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes.

At Months 12 and 24
Change From Baseline in HFMSE Score at Month 24
Tidsram: Baseline, Month 24

HFMSE assessment is performed for participants who are ≥ 2 years and are sitters or walkers. Items on the original HFMS were expanded to capture higher functioning in SMA patients using 13 relevant additional items adapted from the GMFM with their scoring adapted to a three-point scale as in the original HFMS. The score ranges between 0 - 66, a higher score indicates a higher level of function.

Baseline visit correspond with the index date (D1) where the participant was administered the first dose of Risdiplam.

Baseline, Month 24
Number of Participants who Require Ventilatory Assistance
Tidsram: Up to 2 years follow-up per participant

Invasive ventilation and non-invasive ventilation due to respiratory insufficiency. Participants on permanent ventilation and when using it as temporary respiratory support will be assessed.

Up to 2 years follow-up per participant
Duration of Ventilation
Tidsram: Up to 2 years follow-up per participant

Number of hours spent per day of non-invasive or invasive ventilation. Duration for both permanent ventilation and when used as temporary respiratory support will be assessed.

Up to 2 years follow-up per participant
Time Until Permanent Ventilation
Tidsram: Up to 2 years follow-up per participant

Time until permanent ventilation is defined as ≥ 16 hours of non-invasive ventilation per day or intubation for > 21 consecutive days in the absence of, or following the resolution of, an acute reversible event or tracheostomy.

Up to 2 years follow-up per participant
Ventilation-free Survival
Tidsram: Up to 2 years follow-up per participant

Assessed by duration of time from a specified index date until the initiation of permanent ventilation.

Up to 2 years follow-up per participant
Change From Baseline in Growth Pattern
Tidsram: Up to Month 24

Growth patterns will be compared to standardized growth charts.

Up to Month 24
Number of Participants With Musculoskeletal Abnormalities
Tidsram: Up to Month 24

Musculoskeletal abnormalities include scoliosis, kyphosis or other deformities

Up to Month 24
Bulbar Function as Assessed by the Study Physician Versus Baseline
Tidsram: Up to Month 24

Bulbar function measures the ability to feed orally, chew, and ability to swallow versus baseline data. It also assesses the speaking and crying functions of the participant.

Up to Month 24
Number of Participants With Adverse Events (AE) Serious Adverse Events (SAE)
Tidsram: Up to 2 years follow-up per participant

Data for incidence, seriousness, severity, and relatedness of all AEs reported or documented in medical notes by physicians during the safety observation period will also be reported.

Up to 2 years follow-up per participant

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Clinical Trials, Hoffmann-La Roche

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

22 juli 2026

Primärt slutförande (Beräknad)

1 mars 2028

Avslutad studie (Beräknad)

1 mars 2029

Studieregistreringsdatum

Först inskickad

8 april 2026

Först inskickad som uppfyllde QC-kriterierna

8 april 2026

Första postat (Faktisk)

15 april 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera